Skip to main content

A New Era of Alzheimer's Therapeutics: Biomarkers, AI for ARIA Detection, and PET Neuroimaging, presented by the ASNR Alzheimer, ARIA & Dementia Study Group

A New Era of Alzheimer's Therapeutics: Biomarkers, AI for ARIA Detection, and PET Neuroimaging, presented by the ASNR Alzheimer, ARIA & Dementia Study Group

Description & Learning Objectives
Planned and presented by the Alzheimer's/ARIA/Dementia Study Group, with Cyrus Raji, MD, PhD moderating.

1. Update on NIAA Criteria: Clifford Jack
2. Multimodal dementia imaging including AI tools for ARIA surveillance: Suzie Bash
3. Moving to CMS and Amyloid and Tau PET: Ana Franceschi

Upon completion of this activity, participants will gain strategies to:
1. Understand options for fluid and imaging biomarkers in defining Alzheimer's disease and understanding how this may precede the subsequent clinical syndrome of Alzheimer's dementia.
2. Describe new AI tools for ARIA detection.
3. Understand new options for application of brain PET in clinical practice for detection of Alzheimer disease biomarkers.
4. Discuss the neuroimaging pathway for patients with suspected Alzheimer’s disease through clinical case examples.
5. Understand recent updates on DMT including ARIA risk factors and grading.
6. Learn about AI tools which can assist in ARIA surveillance.
Instructions for Participation
To complete this activity, learners will watch a recording of a live webinar and submit a course evaluation. Once all elements are completed, a certificate will be automatically added to your transcript.
Credit Dates
Available: 11/9/2023
Expires: 11/8/2026

Planners & Faculty
Tammie Benzinger, MD, PhD, Planner
Petrice Cogswell, MD, PhD, Planner
Cyrus Raji, MD, PhD, Planner/Moderator
Suzie Bash, MD, Speaker
Ana Franceschi, MD, PhD, Speaker
Clifford Jack, MD, Speaker

Accreditation Statement
The American Society of Neuroradiology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Neuroradiology designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In compliance with ACCME requirements and guidelines, ASNR has developed a policy for disclosure and review of potential conflicts of interest and a method for resolution if a conflict does exist. ASNR maintains a tradition of scientific integrity and objectivity in its educational activities. In order to preserve these values and ensure its educational activities are independent and free of commercial bias, all individuals, including planners, presenters, moderators and evaluators, participating in an ASNR educational activity, or an activity jointly provided by ASNR must disclose all relevant financial relationships with ineligible companies, as defined by the ACCME. Unless listed below, all planners and individuals in control of content have nothing to disclose.

Tammie Benzinger is the Imaging Core Leader for the DIAN-TU, which now includes lecanemab in an ongoing clinical trial, and has participated as a site investigator in clinical trials sponsored by Biogen, Eisai, Eli Lilly, Jansen, and Roche. Has research funding from the NIH and Siemens. Is a consultant to Biogen, Eisai, Eli Lilly, and Bristol Myers Squibb. Dr. Benzinger's employer, Washington University, holds shares in C2N.

Suzie Bash has relationships with Subtle Medical,,, Darmiyan, Merit, Columbo, GE, Guerbet, and Eisai.

Ana Franceschi serves as a consultant for Biogen, Life Molecular Imaging, and Roche/Genentech.

All other participants and planners have no disclosures.

This activity is generously supported by unrestricted educational grants from Eisai & Icometrix.
Other Resources